24 August 2021>: Clinical Research
Different Doses of Nalbuphine Combined with Dexmedetomidine in Laparoscopic Oophorocystectomy
Xiaofen Liu ABCDEF , Jie Song BCDF , Yang Zhang BCDF , Ye Zhang BCDF , Xianwen Hu CDFG*DOI: 10.12659/MSM.930197
Med Sci Monit 2021; 27:e930197
Table 5 Hospitalization time and complications in all patients.
Variables | LND, n=55 | MND, n=54 | HND, n=55 | Control, n=55 | P value |
---|---|---|---|---|---|
Hospitalization, days | 6.20±1.41c | 6.05±1.54c | 4.33±1.14a | 6.94±1.40a | |
Complications, n (%) | 0.650 | ||||
Nausea and vomiting | 3 (5.45) | 2 (3.70) | 2 (3.70) | 3 (5.45) | |
Dizziness and headache | 1 (1.82) | 1 (1.82) | 1 (1.82) | 2 (3.70) | |
Fidgety | 0 (0.00) | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
Skin Itch | 1 (1.82) | 0 (0.00) | 1 (1.82) | 0 (0.00) | |
a b c d LND – low-dose nalbuphine and dexmedetomidine; MDN – middle-dose nalbuphine and dexmedetomidine; HND – high-dose nalbuphine and dexmedetomidine. |